New hope for psoriasis patients who failed standard biologic therapy
NCT ID NCT06945107
First seen Apr 07, 2026 · Last updated May 20, 2026 · Updated 5 times
Summary
This study tests a new medication called picankibart in about 308 adults with plaque psoriasis who did not get enough relief from common biologic drugs (IL-17 inhibitors). Participants will switch to picankibart or an active control to see if it better clears skin symptoms. The trial lasts 48 weeks and focuses on safety and how well the drug works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLAQUE PSORIASIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Dermatology Hospital of Shandong First Medical University (Shandong Provincial Hospitial of Dermatology)
Jinan, Shandong, 250000, China
Conditions
Explore the condition pages connected to this study.